Recently, GLaD reserchers Sean Mulcahy, Emily Lenton and Dion Kagan presented a 3-part showcase of research findings from current projects addressing LGBTIQA+ human rights, hepatitis C data justice, and life after hepatitis C cure. Watch a recording of their papers here.
Our latest article considers Australian insurance law and practice in the context of hepatitis C.
GLaD research lead Kate Seear gave a keynote presentation at the inaugural Australian Stigma Conference hosted by the Australian Injecting & Illicit Drug Users League (AIVL) in Canberra calling for reform to legal, social, policy and cultural dimensions of hepatitis C in order to better to address the health and human rights of people who use drugs.
GLaD program lead Kate Seear and project officer Dion Kagan presented recent findings at The Australian Sociological Association conference earlier this month.
To mark World Hepatitis Day in 2022, researchers in the GLaD and DruGS programs at ARCSHS got together with CEO of Hepatitis Australia Carrie Fowlie to share and discuss findings from three recent social research projects on hepatitis C. Listen to the conversation here.
We are pleased to announce the next publication from our ARC-funded project, ‘Addressing hepatitis C-related legal, policy and practice discrimination in a post-cure world’. Co-authored
The Australian Department of Health will soon embark on developing the sixth iteration of the national hepatitis C strategy, anticipated to be its last, and
The GLaD program was delighted to be invited to participate in the UNSW Centre for Social Health Research series ‘Spotlight on Stigma’, in April 2022.
Each year, the United Nations celebrates two important, interconnected days on its international calendar. The 10th of December marks International Human Rights Day. In 2021,
Earlier in 2021, GLaD program researcher Emily Lenton led an article reporting on this work, titled ‘Upscaling HIV and hepatitis C testing in primary healthcare settings: Stigma-sensitive practice’ in the Australian Journal of Public Health.The article was co-authored with Jen Johnson, previously of the BBV Sector Development Program, and Dr Graham Brown. This article focuses on how healthcare settings can support the goal of upscaling HIV and hepatitis C testing in a way that delivers safe and stigma-free testing encounters.
Each year, on the 31st of August, people around the world come together to mark International Overdose Awareness Day. Initiated in 2001 by Melburnian Sally J Finn, International Overdose Awareness Day is an opportunity to pause, grieve, memorialise lives lost, and to stimulate frank conversations about overdose and other drug-related harms and how to prevent them.
Since late 2019, COVID-19 has been the global health crisis absorbing much of our attention. Efforts to respond to it, including the redeployment of people and resources, have necessarily had impacts on other public health programs and pandemics. The World Health Organization’s ambitious goal to eliminate hepatitis C by 2030 is one program that has been slowed and, in some places, stopped in its tracks by COVID-19.
The Mandatory Disease Testing Act 2021, recently passed through the New South Wales Parliament,establishes a new scheme under which a person can be ordered to provide a blood sample for the testing of blood-borne viruses if, as a result of their deliberate action, their bodily fluid has come into contact with a health, emergency or public sector worker.
Seeking participants for research on people’s lived experience of hepatitis C cure
What does life look like for people after they have cleared hepatitis C?
What does life look like for people after they have cleared hepatitis C? Do people whose blood shows no detectable amount of the hepatitis C virus need to inform their doctor or dentist about their previous hepatitis C status? What about prospective employers or insurance providers? Does hepatitis C–related stigma and discrimination remain a challenge for people post-cure? In what ways, and in what settings?
Australia is spending billions on the universal rollout of direct-acting antiviral drugs (DAAs) as part of its ambitious goal of achieving virtual elimination of hepatitis C by 2030. These ‘revolutionary’, ‘transformative’ drugs can bring about a sustained virological response – that is, a cure – for hepatitis C in over 90 percent of people treated. They are available on the Pharmaceutical Benefits Scheme for all Australians who are covered by Medicare.
As Australia works towards its ambitious target of reducing hepatitis C stigma by 50% by 2022, it is necessary to investigate and understand the issues that continue to affect people who have – and have been treated for – hepatitis C. One significant example of such issues is the set of laws and policies devised in a pre-cure world that have yet to be reformed since the advent of curative treatments. Do people who had hepatitis C need to disclose this to insurers or prospective employers? And could you be refused employment or insurance on such a basis? Does the fact you once had hepatitis C need to be retained in your medical records? There are literally dozens of questions like these to be asked.
In Australia, a new generation of direct-acting antivirals (DAAs) for the treatment of hepatitis C have been rolled out in a globally unique program of
We are excited to announce the publication of the first article from the project, ‘Addressing hepatitis C-related legal, policy and practice discrimination in a post-cure world’.